Cobimetinib plus atezolizumab for <i>RAS</i> and <i>NF</i>1/2-mutated poorly differentiated thyroid carcinoma.Sarah Hamidi, Renata Ferrarotto, Brian McKinley et al.|Journal of Clinical Oncology|2024Cited by 4